Aegerion Pharmaceuticals Acknowledges the National Lipid Association's Revised Guidelines for the Treatment of Familial Hypercholesterolemia

Loading...
Loading...
Aegerion Pharmaceuticals, Inc.
AEGR
today acknowledged the publication of the National Lipid Association's guidelines for the screening, diagnosis and treatment of familial hypercholesterolemia. There are six articles in total published in the April 2011 Journal of Clinical Lipidology summarizing the consensus opinion of the National Lipid Association's Expert Panel on Familial Hypercholesterolemia with respect to the prevalence of the disease and recommended clinical criteria for diagnosis and treatment of pediatric and adult patient populations across the spectrum of FH severity. Aegerion Pharmaceuticals is currently in late-stage clinical development with their drug candidate, Lomitapide, to treat genetic lipid disorders.
Posted In: NewsFDA
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...